Urologic Cancer Program

At Penn Medicine's Abramson Cancer Center, our urologic cancer clinicians and researchers have led the way for years in the diagnosis and treatment of urologic cancers. By putting our experience to work, we offer the best possible treatment outcomes.

Your Team of Experts

If you have been diagnosed with a urologic cancer, you'll want the best team of experts. Our Penn experts have worked together for years to offer high-quality medical care that leads to faster recovery time, and the best chance of being cured. U.S. News & World Report ranks Penn's urology program the highest in the region.

Your urologic cancer team includes:

  • Specialists in urology, medical oncology, surgical oncology, radiation oncology, radiology and pathology
  • Nurses, nurse practitioners, and physician assistants with advanced training and experience in urologic cancer
  • Patient support specialists who are experts in navigating complex health care situations and act as a consistent point of contact and a reliable source for support
  • Cancer counselors who work exclusively with cancer patients and their families
  • Registered dietitians who specialize in cancer nutrition and provide information based on sound nutritional therapies
Like other forms of cancer, the earlier urological cancer is detected, the greater the chance a successful treatment can be implemented.
We provide diagnosis and treatment for:

The Most Advanced Techniques Available

We offer the region's most advanced diagnostic testing, treatments, and technologies. Our urologists are world renowned in cutting-edge surgical techniques, including nerve-sparring and robotically-assisted prostatectomy. We perform more prostatectomies, as well as transurethral and testicular procedures, than any other Greater Philadelphia hospital.

Developmental Therapeutics

Thanks to the backing of major research efforts, remarkable progress has been made in developing therapies for the treatment of cancer. This includes our innovative and highly respected Developmental Therapeutics Program which has launched phase I and phase II clinical trials for patients with androgen-independent prostate cancer.